title: Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction.
abstract: BACKGROUND
  The important role of oxidized low density lipoprotein (oxidized-LDL) in preclinic atherosclerosis and pathophysiology of acute coronary syndromes studies have reported. Oxidation of LDL activates many inflammatory and atherogenic pathways and plays a pivotal role in atherosclerosis. Our aim in this study is to compare the effects of 80 mg daily dose of atorvastatin and 20 mg daily dose of rosuvastatin on lipid profiles and the levels of oxidized-LDL and inflammatory markers in ST elevation myocardial infarction (STEMI).
  
  
  METHODS
  One hundred and twenty patients with STEMI were enrolled in this study. The patients were randomly assigned to receive atorvastatin (80 mg/day) or rosuvastatin (20 mg/day) by using a ratio of 1:1 after revascularization. The levels of total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), LDL-C, apolipoprotein B and apolipoprotein A were compared between groups after 4-week therapy. The values of oxidized-LDL, tumor necrosis factor receptor 1 and 2, Interleukin-6 and hs-CRP were also compared between groups. The Student's t test was used to detect absolute and percent changes between groups, and p < 0.05 was considered as statistically significant for all tests.
  
  
  RESULTS
  After treatment in both treatment groups LDL-C, oxidized-LDL, hs-CRP, tumor necrosis factor receptor 1 and 2, Interleukin-6 values significantly decreased according to baseline. The only difference was in HDL-C levels. HDL-C slightly decreased in atorvastatin group while it increased in the rosuvastatin group compared baseline (-1.4 ± 8.9 mg/dl vs 2.0 ± 9.4 mg/dl, p = 0.04).
  
  
  CONCLUSIONS
  We reported that both statin treatment regiments have comparable effects on LDL-C, oxidized-LDL and inflammatory markers. Moreover, it was observed that rosuvastatin was more effective in terms of ability to increase HDL-C level. Based on these findings, 20 mg daily dose of rosuvastatin may be an alternative to 80 mg daily dose of atorvastatin in patients with acute coronary syndrome.
authors.affiliation: Denizli Servergazi State Hospital, Department of Cardiology, Denizli, Turkey; Denizli State Hospital, Department of Cardiology, Denizli, Turkey. Electronic address: ulkudr@gmail.com.
authors.forename: Meryem Ulku
authors.initials: MU
authors.lastname: Aydin
authors.affiliation: Selcuk University, Selcuklu School of Medicine, Department of Cardiology, Konya, Turkey.
authors.forename: Nazif
authors.initials: N
authors.lastname: Aygul
authors.affiliation: Selcuk University, Selcuklu School of Medicine, Department of Cardiology, Konya, Turkey.
authors.forename: Bulent Behlul
authors.initials: BB
authors.lastname: Altunkeser
authors.affiliation: Selcuk University, Selcuklu School of Medicine, Department of Biochemistry, Konya, Turkey.
authors.forename: Ali
authors.initials: A
authors.lastname: Unlu
authors.affiliation: Dr Faruk Sukan Maternity and Children Hospital, Department of Biochemistry, Konya, Turkey.
authors.forename: Alpaslan
authors.initials: A
authors.lastname: Taner
mesh_terms: D000368:Aged; D000069059:Atorvastatin / Q000008:administration & dosage*; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D018836:Inflammation Mediators / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000097:blood; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000097:blood; D000068718:Rosuvastatin Calcium / Q000008:administration & dosage*; D016896:Treatment Outcome; D014421:Turkey
chemical_list: D015415:Biomarkers; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; C508600:IL6 protein, human; D018836:Inflammation Mediators; D015850:Interleukin-6; D008077:Lipoproteins, LDL; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II; C506235:TNFRSF1A protein, human; C415902:TNFRSF1B protein, human; C099252:oxidized low density lipoprotein; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein; D000069059:Atorvastatin
keywords: Atorvastatin; Inflammatory markers; Lipid parameters; Oxidized-LDL; Rosuvastatin; ST segment elevation myocardial infarction